相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A review of current treatment strategies for infective endocarditis
David Luque Paz et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2021)
Stewarding the Costly Antibiotic: Considerations for Dalbavancin
P. Brandon Bookstaver et al.
CLINICAL INFECTIOUS DISEASES (2021)
Population Pharmacokinetics of Dalbavancin and Dosing Consideration for Optimal Treatment of Adult Patients with Staphylococcal Osteoarticular Infections
Pier Giorgio Cojutti et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives
Massimo Andreoni et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2021)
Efficacy and safety of dalbavancin in the treatment of Gram-positive bacterial infections
Yuhang Wang et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2021)
Dalbavancin Efficacy and Impact on Hospital Length-of-Stay and Treatment Costs in Different Gram-Positive Bacterial Infections
Mariacristina Poliseno et al.
CLINICAL DRUG INVESTIGATION (2021)
Review: A Safety Profile of Dalbavancin for On-and Off-Label Utilization
Oriana Simonetti et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2021)
Dalbavancin Population Pharmacokinetic Modeling and Target Attainment Analysis
Timothy J. Carrothers et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2020)
In vitro time-kill kinetics of dalbavancin against Staphylococcus spp. biofilms over prolonged exposure times
Vincenzo Di Pilato et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2020)
Dalbavancin as a second-line treatment in methicillin-resistant Staphylococcus aureus prosthetic vascular graft infection
Arturo Ciccullo et al.
INFECTION (2020)
Receipt of supratherapeutic dalbavancin
Monica V. Mahoney et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2020)
Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients
E. T. Van Matre et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Successful treatment of methicillin-sensitive Staphylococcus aureus tricuspid-valve endocarditis with dalbavancin as an outpatient in a person who injects drugs: A case report
Aaron Hakim et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)
Dalbavancin versus standard of care for the treatment of osteomyelitis in adults: A retrospective matched cohort study
Thamer A. Almangour et al.
SAUDI PHARMACEUTICAL JOURNAL (2020)
Dalbavancin combined with linezolid in prosthetic-hip infection
Isabel Maria Carrion Madronal et al.
REVISTA ESPANOLA DE QUIMIOTERAPIA (2020)
Therapeutic Drug Monitoring of Dalbavancin Treatment in Severe Necrotizing Fasciitis in 3 Critically Ill Patients: A Grand Round
Alberto Corona et al.
THERAPEUTIC DRUG MONITORING (2020)
Current trends in the real-life use of dalbavancin: report of a study panel
Emanuele Durante-Mangoni et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: A systematic review
Geren Thomas et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Use of a Standardized Dalbavancin Approach to Facilitate Earlier Hospital Discharge for Vulnerable Patients Receiving Prolonged Inpatient Antibiotic Therapy
Axel A. Vazquez Deida et al.
OPEN FORUM INFECTIOUS DISEASES (2020)
Outpatient Parenteral Antimicrobial Therapy in the Time of COVID-19: The Urgent Need for Better Insurance Coverage
Omar Mansour et al.
OPEN FORUM INFECTIOUS DISEASES (2020)
Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study)
Francesca Bai et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2020)
Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections
Michael P. Veve et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Dalbavancin in the Treatment of Bacteremia and Endocarditis in People with Barriers to Standard Care
Leama Ajaka et al.
ANTIBIOTICS-BASEL (2020)
Enterococcus faecalis Endocarditis and Outpatient Treatment: A Systematic Review of Current Alternatives
Laura Herrera-Hidalgo et al.
ANTIBIOTICS-BASEL (2020)
Dalbavancin, Vancomycin and Daptomycin Alone and in Combination with Cefazolin against Resistant Phenotypes of Staphylococcus aureus in a Pharmacokinetic/Pharmacodynamic Model
Jacinda C. Abdul-Mutakabbir et al.
ANTIBIOTICS-BASEL (2020)
Dalbavancin Reduces Hospital Stay and Improves Productivity for Patients with Acute Bacterial Skin and Skin Structure Infections: The ENHANCE Trial
Matthew W. McCarthy et al.
INFECTIOUS DISEASES AND THERAPY (2020)
Safety and Efficacy of Prolonged Use of Dalbavancin in Bone and Joint Infections
L. Morata et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Clinical experience with dalbavancin for the treatment of deep sternal wound infection
Michele Bartoletti et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2019)
Dalbavancin as Secondary Therapy for Serious Staphylococcus aureus Infections in a Vulnerable Patient Population
Chloe Bryson-Cahn et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
Multicenter clinical experience of real life Dalbavancin use in gram-positive infections
S. Wunsch et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2019)
Single-dose dalbavancin and patient satisfaction in an outpatient setting in the treatment of acute bacterial skin and skin structure infections
Urania Rappo et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2019)
Long-Acting Lipoglycopeptides: Lineless Antibiotics for Serious Infections in Persons Who Use Drugs
Taylor Morrisette et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
Epithelial Lining Fluid and Plasma Concentrations of Dalbavancin in Healthy Adults after a Single 1,500-Milligram Infusion
Urania Rappo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection
Selma Tobudic et al.
INFECTION (2019)
French national cohort of first use of dalbavancin: A high proportion of off-label use
Aurelien Dinh et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Dalbavancin use in an academic medical centre and associated cost savings
Amber C. Streifel et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Left Ventricular Assist Device Infections and the Potential Role for Dalbavancin: A Case Report
Jessica Howard-Anderson et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
Serum Bactericidal Activity Levels Monitor to Guide Intravenous Dalbavancin Chronic Suppressive Therapy of Inoperable Staphylococcal Prosthetic Valve Endocarditis: A Case Report
Martina Spaziante et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections
Yohei Doi
CLINICAL INFECTIOUS DISEASES (2019)
DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci
Carmen Hidalgo-Tenorio et al.
ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS (2019)
Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of Staphylococcus aureus in a Simulated Pharmacodynamic/Pharmacokinetic Model
Razieh Kebriaei et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Dalbavancin for the management of gram-positive osteomyelitis: Effectiveness and potential utility
Thamer A. Almangour et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2019)
Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety
Urania Rappo et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections
Jacqueline T. Bork et al.
INFECTIOUS DISEASES AND THERAPY (2019)
Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin
J. M. Steele et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2018)
Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna
Selma Tobudic et al.
CLINICAL INFECTIOUS DISEASES (2018)
Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen
B. J. Werth et al.
CLINICAL MICROBIOLOGY AND INFECTION (2018)
Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis
R. Agarwal et al.
CLINICAL MICROBIOLOGY AND INFECTION (2018)
Dalbavancin is active in vitro against biofilms formed by dalbavancin-susceptible enterococci
Katharina Neudorfer et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2018)
Treatment with dalbavancin in a patient with septic thrombophlebitis of the internal jugular vein due to Staphylococcus aureus after insertion of an implantable cardioverter defibrillator
Javier Martinez-Sanz et al.
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA (2018)
Dalbavancin treatment of prosthetic knee infection due to oxacillin-resistant Staphylococcus epidermidis
Maria Ramirez Hidalgo et al.
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA (2018)
Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016)
Michael A. Pfaller et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)
Dalbavancin in the treatment of different gram-positive infections: a real-life experience
Emilio Bouza et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)
Dalbavancin treatment in a deep sternal wound MRSA infection after coronary artery bypass surgery: a case report
Aneta Guzek et al.
JOURNAL OF CARDIOTHORACIC SURGERY (2018)
Successful treatment of Enterococcus faecalis bacteremia with dalbavancin as an outpatient in an intravenous drug user
Bruce M. Jones et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2018)
Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis
Manuel Kussmann et al.
EMERGING MICROBES & INFECTIONS (2018)
Septic arthritis in a native knee due to Corynebacterium striatum
Juan Molina Collada et al.
REUMATOLOGIA CLINICA (2018)
In vitro activity of daptomycin combined with dalbavancin and linezolid, and dalbavancin with linezolid against MRSA strains
Gulseren Aktas et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Dalbavancin Pharmacokinetics and Safety in Children 3 Months to 11 Years of Age
Daniel Gonzalez et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2017)
Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic
Ranjeet Prasad Dash et al.
INFECTIOUS DISEASES (2017)
Dalbavancin Use for the Treatment of Methicillin-resistant Staphylococcus aureus Pneumonia
Katie E. Barber et al.
JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS (2017)
A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection
Michael W. Dunne et al.
CLINICAL INFECTIOUS DISEASES (2016)
Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies
Michael W. Dunne et al.
DRUG SAFETY (2016)
In vitro activity of dalbavancin against biofilms of staphylococci isolated from prosthetic joint infections
Javier Fernandez et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2016)
Impact of Glycopeptide Resistance in Staphylococcus aureus on the Dalbavancin In Vivo Pharmacodynamic Target
A. Lepak et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Extended-Duration Dosing and Distribution of Dalbavancin into Bone and Articular Tissue
Michael W. Dunne et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
A thorough QT study with dalbavancin: A novel lipoglycopeptide antibiotic for the treatment of acute bacterial skin and skin-structure infections
Michael W. Dunne et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2015)
Treatment of methicillin-sensitive Staphylococcus aureus bacteremia secondary to septic phlebitis using dalbavancin
J. C. Cho et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2015)
Pharmacokinetics, Safety and Tolerability of Single Dose Dalbavancin in Children 12-17 Years of Age
John S. Bradley et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2015)
Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection
Helen W. Boucher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection model
Daniela Baldoni et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2013)
Systemic Antibiotic Therapy for Chronic Osteomyelitis in Adults
Brad Spellberg et al.
CLINICAL INFECTIOUS DISEASES (2012)
Pharmacokinetics of Dalbavancin in Patients With Renal or Hepatic Impairment
Thomas Marbury et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Pharmacokinetics of dalbavancin in plasma and skin blister fluid
David P. Nicolau et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
In vivo pharmacodynamic activity of the glycopeptide dalbavancin
David Andes et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004)
RN Jones et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2006)
Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide
M Buckwalter et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens
I Raad et al.
CLINICAL INFECTIOUS DISEASES (2005)
分享论文
